Diffusion Therapeutics (DFTX) Drops 9% Ahead of Anxiety Disorder Clinical Data
DFTX Definium Therapeutics Inc
$40.91 -9.39%
View chart & analysis → - 1Diffusion Therapeutics (DFTX) shares fell 9% on Tuesday, headed for their worst day since early November.
- 2Results from the once-daily treatment DT120 in a late-stage clinical trial for generalized anxiety disorder are due this week (week of Aug. 10), with data from a second anxiety study set for September.
- 3The market is watching to see whether the benefits already demonstrated in depression extend to anxiety disorders.
This 3-line summary is compiled from the report below.
Stocktwits +1 View original ↗🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다